The use and safety risk of repurposed drugs for COVID-19 patients: lessons learned utilizing the Food and Drug Administration’s Adverse Event Reporting System-Reference-Cited by-同舟云学术

The use and safety risk of repurposed drugs for COVID-19 patients: lessons learned utilizing the Food and Drug Administration’s Adverse Event Reporting System

Published:2023-07 Issue:7 Volume:31 Page:1360-1366
ISSN:1319-0164
Container-title:Saudi Pharmaceutical Journal
language:en
Short-container-title:Saudi Pharmaceutical Journal

Author:

Alsuhaibani Deemah S.,Edrees Heba H.,Alshammari Thamir M

Publisher

Elsevier BV

Subject

Pharmaceutical Science,Pharmacology

Reference30 articles.

1. Risk of adverse drug events following the virtual addition of COVID-19 repurposed drugs to drug regimens of frail older adults with polypharmacy;Al Rihani;J. Clin. Med.,2020

2. Empirical estimation of under-reporting in the US Food and Drug Administration adverse event reporting system (FAERS);Alatawi;Expert Opin. Drug Saf.,2017

3. Risk of hepatotoxicity associated with fluoroquinolones: a national case–control safety study;Alshammari;Am. J. Health Syst. Pharm.,2014

4. Signals of bleeding among direct-acting oral anticoagulant users compared to those among warfarin users: analyses of the post-marketing FDA Adverse Event Reporting System (FAERS) database, 2010–2015;Alshammari;Ther. Clin. Risk Manag.,2018

5. Efficacy and safety of remdesivir in hospitalised COVID-19 patients: a systematic review and meta-analysis;Angamo;Infection,2021

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pancreatitis with use of new diabetic medications: a real-world data study using the post-marketing FDA adverse event reporting system (FAERS) database;Frontiers in Pharmacology;2024-05-27

2. Model for predicting risk of developing drug-induced liver injury during remdesivir therapy: observational prospective open case-control study;Pharmacy & Pharmacology;2023-11-20

3. Adverse events associated with molnupiravir: a real-world disproportionality analysis in food and drug administration adverse event reporting system;Frontiers in Pharmacology;2023-10-31